Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Media Commentary
-
By Kevin E. Noonan — And all patent rights are theft, according to The New York Times. In but one small story on its business pages, the "newspaper of record" misstates the facts, impugns the law, and slanders one of the greatest American inventors who ever lived (see "Edison . . . Wasn’t…
-
By Kevin E. Noonan — Insidious (adj.): operating or proceeding in an inconspicuous or seemingly harmless way but actually with grave effect. On Saturday, The New York Times published an article analogizing two industries most readers would not have thought to be similar: the perfume industry and innovator pharmaceutical companies (see "Ahh, the…
-
By Kevin E. Noonan — Continuing its obliquely negative coverage of U.S. Patent law, Peter Lattman of The Wall Street Journal is shocked (shocked!) to find that the University of California is immune from patent infringement suits, despite being an avid participant in obtaining patents on technology developed by its faculty researchers. In…
-
By Donald Zuhn — As we reported yesterday, the San Francisco Chronicle waded into the patent reform debate over the weekend, appearing to have aligned itself with the "laptop" (or tech) group over the "pill bottle" (or biotech/pharma) group. In making a case for the tech firms’ position that patent reform is "badly…
-
By Donald Zuhn — In an editorial appearing in Sunday’s edition of the San Francisco Chronicle, the Bay area newspaper appears to have, perhaps not surprisingly, taken sides with tech companies on the issue of patent reform. In an editorial entitled "The laptop vs. the pill bottle," the Chronicle acknowledges the ongoing battle…
-
By Kevin E. Noonan — It’s beginning to seem like a week cannot go by without The New York Times publishing an article, frequently not on the Op-Ed page but with its news stories, purporting to show that patents are a bad thing – for business, for the country, and sometimes, it seems,…
-
By Christopher P. Singer — In a February 7, 2007 Wall Street Journal article entitled: "Small Firms Seek to Profit From Drug Giants' Castoffs" (subscription required), Jeanne Whalen discusses a drug development strategy that is more frequently being employed by small drug companies. In particular, smaller companies employing this strategy enter into agreements…
-
By Kevin Noonan — In several recent posts, I have taken the position that patents, particularly patents on genes and recombinant or transgenic non-human organisms, have been vital to America's preeminence in the biotechnology and pharmaceutical industries. A recent Washington Post story by Joseph Fuller and Brock Reeve supports this view. The statistics…
-
By Kevin Noonan — The New York Times continued its recent campaign against patents this week, running an Op-Ed piece by Denise Caruso on gene patenting. Perhaps this attack is rooted in the Times loss before the Supreme Court a few years ago when it tried to usurp copyright from authors for online…
-
By Kevin Noonan — Once again, the popular press, aided and abetted by academics more interested in career advancement than the facts, have sounded the clarion call against patenting genes (see "Gene Patenting in the News Again"). For anyone interested in a reasoned debate on an important topic, the resulting articles are disheartening. …
Patent Docs 